Exudative Macular Degeneration
9
2
2
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
22%
2 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (9)
MMP-9 Inhibition for Recalcitrant Wet AMD
CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD
Pilot Study of X-82 in Patients With Wet AMD
Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment
Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration